Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Recruiting now · Phase 1/Phase 2
Conditions studied: Advanced Solid Tumor
In brief
Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab. The study now includes a monotherapy cohort targeting visceral lesions and a separate Phase 2 monotherapy cohort for advanced melanoma.
Key facts
- Study ID
- NCT06249048
- Run by
- Strand Therapeutics Inc.
- People needed
- 108
- Starts
- 2024-05-03
- Expected to finish
- 2028-11-01
- Last updated by the study team
- 2025-10-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States (enrolling)
- NextGen Oncology — Beverly Hills, California, United States (enrolling)
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- Melanoma Institute Australia — Wollstonecraft, Australia (enrolling)
- Huntsman Cancer Institute - University of Utah — Salt Lake City, Utah, United States
- Cleveland Clinic — Cleveland, Ohio, United States
- HonorHealth Research and Innovation Institute — Scottsdale, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.